MCL Clinical Trials

4 recruiting

MCL Trials at a Glance

18 actively recruiting trials for mcl are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in New York, Duarte, and Beijing. Lead sponsors running mcl studies include Ruijin Hospital, Peking University Third Hospital, and Sun Yat-sen University.

Browse mcl trials by phase

Treatments under study

About MCL Clinical Trials

Looking for clinical trials for MCL? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MCL trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MCL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 2

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more
Cogent Biosciences, Inc.140 enrolled42 locationsNCT04996875
Recruiting
Phase 2

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

RituximabMCLBTKi+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT07257055
Recruiting
Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+2 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 1

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Mantle Cell LymphomaMCL
Memorial Sloan Kettering Cancer Center39 enrolled10 locationsNCT06192888
Recruiting
Phase 2

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

MCLRelapsed or Refractory Mantle Cell Lymphoma (MCL)
Peking University Third Hospital43 enrolled1 locationNCT07460362
Recruiting
Phase 1

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc.42 enrolled5 locationsNCT07121946
Recruiting
Phase 2

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)Large B Cell Diffuse Lymphoma
Sun Yat-sen University30 enrolled3 locationsNCT07077512
Recruiting
Phase 1

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Non-Hodgkin LymphomaMantle Cell Lymphoma (MCL)CNS Lymphoma+1 more
University of Colorado, Denver68 enrolled1 locationNCT05098613
Recruiting
Phase 2

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea50 enrolled16 locationsNCT07285590
Recruiting
Phase 2

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Mantle Cell Lymphoma (MCL)
Ruijin Hospital25 enrolled1 locationNCT07272499
Recruiting
Not Applicable

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)POZ
Peking University Third Hospital34 enrolled1 locationNCT07257510
Recruiting
Phase 2

Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

Mantle Cell Lymphoma (MCL)
Ruijin Hospital45 enrolled1 locationNCT07199296
Recruiting
Phase 2

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)
Sun Yat-sen University50 enrolled1 locationNCT06846489
Recruiting
Phase 2

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

MCL
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT06463691
Recruiting

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Mantle Cell Lymphoma (MCL)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company300 enrolled1 locationNCT06788652
Recruiting
Phase 1

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

Mantle Cell Lymphoma (MCL)Primary Mediastinal B-cell Lymphoma (PMBCL)
Second Affiliated Hospital, School of Medicine, Zhejiang University52 enrolled1 locationNCT06464861
Recruiting
Phase 3

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Mantle Cell Lymphoma (MCL)
Ruijin Hospital78 enrolled1 locationNCT06496308